HRT doctor skipping labs

When a doctor prescribes hormone replacement therapy without ordering any lab work beforehand, they are technically operating within what the prescribing guidelines allow, because there is no formal requirement that bloodwork be completed before a prescription is written. That absence of a rule does not mean skipping labs is safe or appropriate, and understanding why requires knowing what those labs are actually measuring and why each number matters before any hormone is introduced into the body.

The female hormonal system is built around a cycle of rising and falling signals that talk to each other constantly, and disrupting that conversation without first listening to it is where problems start. The system begins in a region of the brain called the hypothalamus, which releases something called GnRH, which is gonadotropin-releasing hormone, and that signal travels down to the pituitary gland and tells it to release two more hormones. Those two hormones are something called FSH, which is follicle-stimulating hormone, and something called LH, which is luteinizing hormone, and together they travel through the blood to the ovaries and drive the entire monthly cycle of egg development and hormone production.

FSH is the hormone that wakes up a group of follicles, which are small fluid-filled sacs inside the ovary that each contain an immature egg, and as those follicles grow they start producing estrogen. One follicle eventually becomes dominant and produces a surge of estrogen that feeds back to the pituitary and triggers a sudden spike in LH, and that LH surge is what causes ovulation, meaning the release of the mature egg. After ovulation, the leftover follicle transforms into something called the corpus luteum, which is a temporary structure that produces progesterone to prepare the uterus for a possible pregnancy, and if no pregnancy happens the corpus luteum breaks down, progesterone drops, and the cycle resets.

Running labs for FSH and LH gives a doctor a window into whether that entire signaling chain is working the way it should be. Elevated FSH in particular can be a sign that the ovaries are struggling to respond to the signal, because the pituitary keeps sending more and more FSH trying to get a reaction, and that pattern is associated with declining ovarian reserve, which is the remaining supply of eggs. Checking LH alongside FSH lets the doctor see whether the ratio between those two signals is off, which can suggest conditions that would change how HRT should be approached entirely.

Something called AMH, which is anti-Müllerian hormone, is produced directly by the small follicles in the ovaries and gives a more stable and direct read on how much ovarian reserve a woman actually has remaining. Unlike FSH and LH, AMH does not fluctuate dramatically across the menstrual cycle, so it provides a relatively consistent baseline signal, and research has shown it to be one of the more reliable markers for predicting where a woman is in her reproductive timeline and how close she may be to menopause. Knowing this number before starting any hormone intervention is important because a woman with very low AMH is in a fundamentally different hormonal situation than one with normal or high AMH, and treating them identically without that information risks pushing the system in the wrong direction.

Total testosterone and free testosterone matter because testosterone in women is not just a male hormone that happens to be present in small amounts. It plays a real role in energy, mood, libido, and muscle maintenance, and women can experience deficiency symptoms that go unrecognized for years because this is not something most doctors measure routinely in female patients. Free testosterone specifically refers to the portion of testosterone that is not bound to proteins and is actually available for the body to use, because most testosterone circulates attached to something called SHBG, which is sex hormone binding globulin, a protein made primarily in the liver that acts like a carrier and transport protein for several hormones at once.

SHBG is worth its own attention because estradiol, which is the main form of estrogen produced by the ovaries, directly influences how much SHBG the liver makes, and this creates a feedback relationship that changes depending on where a woman is in her cycle and what any external hormone might do to that balance. If someone is given estrogen without knowing their baseline SHBG level, the estrogen can drive SHBG upward, which then binds more testosterone and potentially leaves the body with less free testosterone than before, even if the total amount looks fine on paper. This is one concrete example of how prescribing a hormone without a complete picture of the starting point can produce an outcome the patient and doctor were not expecting.

The other layer of complexity is that the female hormonal system is not static even within a single month. Hormone levels shift significantly from week to week depending on where a woman is in her menstrual cycle, so a single blood draw on one day captures only a snapshot of one phase and not the full picture of how that system is functioning across time. This is why testing multiple times over the first few months of any intervention, while expensive, gives a much more accurate picture of what is actually happening and where adjustments need to be made before the wrong pattern gets established.

The research on gene expression in immune cells across the menstrual cycle shows that even cells in the blood that are not obviously hormone-related are responding to these fluctuating signals in measurable ways, which illustrates how broadly the effects of ovarian hormones reach across the body. Prescribing into that kind of complexity without mapping what the baseline looks like is not a conservative approach, it is actually a less informed one that can create downstream problems in systems the prescribing doctor may not be monitoring at all.

Female hormone optimization has historically received less clinical attention and research investment than male hormone optimization, and the result is that many practitioners are working with older frameworks that do not reflect what is now understood about how interconnected these markers are. The appropriate response to that gap is more thorough evaluation at the outset, not less, and a doctor who is skipping that evaluation entirely is operating with a level of certainty about a patient's hormonal status that the available information simply does not support.

References

1. Brundin PMA, Landgren BM, Fjällström P et al.. Expression of Sex Hormone Receptor and Immune Response Genes in Peripheral Blood Mononuclear Cells During the Menstrual Cycle. Front Endocrinol Lausanne. 2021. Source
2. Odlind V, Elamsson K, Englund DE et al.. Effects of oestradiol on sex hormone binding globulin. Acta Endocrinol Copenh. 1982. Source
3. Yie SM, Wang R, Zhu YX et al.. Circadian variations of serum sex hormone binding globulin binding capacity in normal adult men and women. J Steroid Biochem. 1990. Source
4. Fanis P, Neocleous V, Papapetrou I et al.. Gonadotropin-Releasing Hormone Receptor GnRHR and Hypogonadotropic Hypogonadism. Int J Mol Sci. 2023. Source
5. Richards JS, Pangas SA. The ovary: basic biology and clinical implications. J Clin Invest. 2010. Source
6. Holesh JE, Bass AN, Lord M. Physiology, Ovulation. . 2026. Source
7. Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020. Source
8. Nelson SM, Davis SR, Kalantaridou S et al.. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Hum Reprod Update. 2023. Source
9. Dewailly D, Andersen CY, Balen A et al.. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014. Source

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness